Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences, Inc. (NASDAQ:ENSC) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totaling 364,278 shares, an increase of 619.9% from the May 31st total of 50,601 shares. Approximately 2.4% of the company’s stock are sold short. Based on an average trading volume of 1,391,722 shares, the short-interest ratio is currently 0.3 days.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ENSC. Virtu Financial LLC acquired a new stake in shares of Ensysce Biosciences during the 3rd quarter valued at about $34,000. Citadel Advisors LLC acquired a new position in Ensysce Biosciences in the third quarter worth approximately $34,000. Adage Capital Partners GP L.L.C. increased its holdings in Ensysce Biosciences by 100.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after buying an additional 75,000 shares during the last quarter. Finally, DRW Securities LLC raised its position in Ensysce Biosciences by 42.4% during the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after acquiring an additional 29,336 shares in the last quarter. 5.63% of the stock is owned by institutional investors and hedge funds.

Ensysce Biosciences Stock Up 6.3%

Shares of NASDAQ:ENSC traded up $0.02 during trading on Friday, reaching $0.30. 2,232,292 shares of the company traded hands, compared to its average volume of 1,168,222. The firm has a fifty day simple moving average of $0.33 and a 200 day simple moving average of $0.59. The firm has a market cap of $4.62 million, a P/E ratio of -0.09 and a beta of 0.83. Ensysce Biosciences has a 1-year low of $0.23 and a 1-year high of $2.75.

Ensysce Biosciences (NASDAQ:ENSC) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.21. The business had revenue of $0.96 million for the quarter, compared to the consensus estimate of $1.00 million. Ensysce Biosciences had a negative net margin of 250.39% and a negative return on equity of 766.45%. As a group, research analysts anticipate that Ensysce Biosciences will post -1.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.